peptides for FAQ

Oral KPV in enteric-coated capsules achieves 30–35% bioavailability. Sufficient for localised GI tract effects but inadequate for systemic anti-inflammatory action. BPC-157 tolerates oral administration better than most peptides due to its cyclic structure, and published protocols use 500 mcg oral doses twice daily. Thymosin Alpha-1 cannot be taken orally. It degrades completely in gastric acid and must be injected subcutaneously. If injection is not viable, BPC-157 is the only peptide with meaningful oral efficacy.

PT-141 is the peptide designed specifically for this scenario. Hypoactive sexual desire disorder in premenopausal women with normal estrogen and testosterone is precisely the indication for which bremelanotide received FDA approval. The RECONNECT trials excluded women with hormone deficiencies to isolate the central dopaminergic effect. If standard hormone panels (estradiol, total and free testosterone, DHEA-S) return within normal ranges but libido remains impaired, PT-141's melanocortin-4 receptor mechanism bypasses the hormonal pathway entirely.

MK 677 is orally bioavailable and produces documented lean mass increases at 25mg daily dosing. Most other peptides. CJC-1295, Ipamorelin, BPC-157, Hexarelin. Are degraded by gastric enzymes and require subcutaneous or intramuscular injection to reach systemic circulation intact. Collagen peptides are an exception: hydrolysed fragments survive digestion and show approximately 95% intestinal absorption. Oral collagen at 15g daily produces measurable increases in collagen synthesis markers. If needle aversion is absolute, focus on MK 677 and collagen peptides. But accept that you're excluding secretagogues with stronger GH pulse profiles.

Switching compounds immediately is premature—immune recovery and tissue repair operate on timescales measured in weeks to months, not days. Thymalin's T-cell modulation requires 10-day cycles to influence lymphocyte populations, and TB-500's tissue-repair signaling needs 4–6 weeks to manifest in functional recovery metrics. If no improvement occurs after completing a full protocol duration (10 days for Thymalin, 4–6 weeks for TB-500/BPC-157), reassess the injury profile—neurological presentations require different peptides than cardiac or immune-specific injuries. Storage and reconstitution errors account for 30–40% of reported "non-response" cases—verify that peptides were stored at 2–8°C continuously and reconstituted with correct solvents.

Acute + chronic phase pairing works: Cerebrolysin (acute neuroprotection) followed by Dihexa (chronic neuroplasticity) addresses sequential injury phases without overlapping mechanisms. Avoid combining peptides with redundant pathways. Stacking two BDNF mimetics achieves no additive benefit and increases cost without improving outcomes. Inflammation modulators like Thymalin pair well with neuroplasticity compounds because they target orthogonal mechanisms.

First-dose non-response occurs in approximately 20% of users. Melanocortin receptor density varies individually, and some patients require dose titration to reach threshold. Increase to 1.25mg for the second administration. If no response occurs after two doses at 1.25mg, assess medication storage and reconstitution technique. Temperature excursions during shipping or improper mixing account for most true non-response cases. A peptide that was exposed to ambient temperature above 8°C for more than six hours may appear normal but retain minimal bioactivity.

Start with immune restoration before addressing neurological symptoms. Chronic immune activation and elevated inflammatory cytokines drive neuroinflammation. Treating the upstream immune dysfunction often reduces downstream cognitive issues without direct neuroprotective intervention. Thymalin should be the first-line research compound, with Cerebrolysin or Dihexa added after 4–6 weeks if cognitive symptoms persist despite normalized inflammatory markers. Combining immune and neuroprotective peptides simultaneously can obscure which intervention is driving improvement and complicates dosing adjustments.

Start with KPV for immediate anti-inflammatory support. 500–1000mcg subcutaneously daily reduces symptom severity (fatigue, joint pain, cognitive fog) within 7–14 days without suppressing the immune response required to control viral replication. Thymalin should be added after the acute phase (2–4 weeks into KPV) to address the underlying immune deficiency that allowed reactivation. Starting both simultaneously risks overwhelming an already exhausted immune system with conflicting signals.

Two weeks is insufficient for neurotrophic peptides like Cerebrolysin or Dihexa. Synaptic remodelling requires 4–8 weeks to manifest behaviourally. For acute-acting compounds like Selank, lack of effect suggests inadequate dosing, improper administration route, or peptide degradation. Verify reconstitution technique: was the peptide stored correctly before and after mixing? Was bacteriostatic water used (not sterile water, which has no preservative)? Intranasal administration of Selank requires mucosal contact. Swallowing the solution negates bioavailability.

If you're in the 60–70% of PTSD patients who don't achieve full remission on SSRIs, peptides might address pathways your current treatment doesn't engage. But they aren't replacements. SSRIs modulate serotonin; peptides like Selank target GABA, Semax targets BDNF, and BPC-157 targets inflammation. These are complementary mechanisms, not competing ones. Research protocols typically combine peptides with ongoing therapy and medication rather than substituting them outright.

Resume at the next scheduled dose. Do not double-dose to

Use Hexarelin at 100–200mcg subcutaneously before anticipated stressors. Research models show 14–22% blunting of ACTH-driven cortisol surges without affecting basal cortisol levels. This peptide works through ghrelin receptor pathways that modulate the acute stress response, not chronic HPA axis output. Cycle 5 days on / 2 days off to prevent receptor downregulation, which occurs with continuous daily dosing beyond 4–6 weeks. Pair with magnesium glycinate (400mg daily) to support GABA receptor function and amplify the stress-blunting effect.

This signals excessive aromatization of peptide-restored testosterone to estradiol. Check estradiol levels. If above 40 pg/mL, add a low-dose aromatase inhibitor (anastrozole 0.25 mg twice weekly) or consider a SERM like tamoxifen 10 mg daily to block estrogen receptor activation in breast tissue. The peptides themselves don't cause gynecomastia. They restore testosterone production, but your individual aromatase expression determines how much converts to estrogen. Men with high body fat (>25%) or genetic polymorphisms in the CYP19A1 gene aromatize more aggressively and require proactive estrogen management even on peptide protocols.

Those are known effects of MK 677. Ghrelin mimetics increase hunger signaling through GHSR-1a activation. The effect is dose-dependent: lower doses (10–15 mg) produce milder appetite changes than higher doses (25 mg). Water retention typically resolves within 2–3 weeks as the body adjusts to elevated GH and IGF-1 levels. If retention persists or worsens, reduce dosing or discontinue the protocol. Prolonged fluid retention can mask other metabolic changes and confound data interpretation.

Epithalamin, DSIP, and Selank have decades of research in Eastern European clinical settings with no documented organ toxicity or dependency at therapeutic doses. The primary safety consideration is purity and sourcing. Compounded peptides from unverified suppliers may contain bacterial endotoxins or incorrect amino acid sequences that cause immune responses. Work only with suppliers providing third-party purity verification (HPLC and mass spectrometry) and consider peptides as periodic interventions (10-day cycles every 3–6 months) rather than daily indefinite use.

NSAID-induced ulcers occur because COX-1 inhibition reduces prostaglandin E2, which normally protects the gastric mucosa by stimulating mucus and bicarbonate secretion. TB-500 may help by accelerating epithelial migration even while prostaglandin synthesis remains suppressed. The peptide doesn't restore prostaglandin levels. It bypasses that pathway entirely by enhancing the mechanical process of epithelial cells moving across the ulcer bed. Dosing protocols in wound healing studies typically use 2–10 mg subcutaneously twice weekly.

Yes, unless combined with penetration enhancement. TB-500's molecular weight (4963 Da) prevents dermal penetration through intact stratum corneum—Franz cell studies show less than 0.5% absorption. Microneedling at 1.5 mm depth immediately before TB-500 application increases dermal deposition by 10–30×, but even then, systemic injection (subcutaneous at 2–5 mg twice weekly) produces more consistent follicle exposure. Patients using TB-500 systemically for musculoskeletal recovery report hair texture and density improvements as secondary effects, but no controlled trials exist. If pursuing TB-500 for hair-specific outcomes, microneedling-assisted delivery is the minimum viable approach.

Never double-dose peptides to compensate for missed injections. BPC-157's mechanism depends on sustained signaling, not peak plasma levels. Doubling a dose doesn't 'make up' for the gap. If you miss 2–3 consecutive days of BPC-157, resume at the standard 250–500 mcg dose and extend the cycle by the number of missed days. If you miss a TB-500 injection (scheduled twice weekly), administer it as soon as you remember if fewer than 4 days have passed, then resume the regular schedule. If more than 4 days have passed, skip the missed dose entirely and continue with the next scheduled injection. Missing a full week of TB-500 doesn't require restarting. The half-life is long enough that plasma levels remain detectable for 7–10 days.

Use subcutaneous or intraperitoneal routes for systemic peptide delivery, but expect reduced brain tissue concentrations. Intranasal administration bypasses the blood-brain barrier and hepatic first-pass metabolism. P21 delivered intranasally achieves 10–15× higher hippocampal concentrations than equivalent systemic doses in rodent pharmacokinetic studies. If intranasal delivery is impractical (common in larger animal models or when blinding is required), increase the systemic dose proportionally and verify brain tissue levels through endpoint assays. Some research groups use intraventricular injection for direct CNS delivery, though this introduces surgical confounds in TBI models.

Simultaneous administration of Thymalin, KPV, and growth hormone secretagogues carries no documented contraindications in research literature, but receptor saturation becomes a concern with continuous use. Thymalin protocols in published studies use 10-day cycles with 20-day rest periods to prevent thymic adaptation. Growth hormone secretagogues demonstrate sustained efficacy with 5-days-on, 2-days-off patterns that prevent desensitization of pituitary GH-releasing receptors. KPV shows no tolerance development in animal models, but human data remains limited. Conservative protocol design staggers peptide introduction. Begin with one compound, assess response over 4–6 weeks, then layer additional peptides if needed.